XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Fair Value of Options
The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Expected stock price volatility62.7 %74.2 %65.8 %75.2 %
Risk free interest rate0.8 %0.3 %0.5 %1.6 %
Expected life of options (years)5.45.75.45.7
Expected annual dividend per share$— $— $— $— 
Schedule of Stock Options Activity A summary of the Company's stock options for the nine months ended September 30, 2021 were as follows:
Number of
Shares		Weighted Average Exercise 
Price		Weighted Average Remaining
Years		Aggregate
Intrinsic
Value
 (in thousands)  (in millions)
Options outstanding, December 31, 202014,032 $9.54   
Granted2,896 $17.20   
Exercised(1,193)$7.19   
Forfeited(739)$12.76   
Expired(198)$13.36 
Options outstanding, September 30, 202114,798 $11.02 6.5$13.8 
Vested and unvested expected to vest, September 30, 202113,460 $10.81 6.4$13.8 
Exercisable at September 30, 20219,071 $9.42 5.2$13.6 
Schedule of Non-Vested RSU Activity under the Plan A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2021 is as follows:
Number of
Shares		Weighted
Average Grant
Date Fair
Value		Weighted 
Average
Remaining 
Years		Aggregate
Intrinsic
Value
(in thousands)(in millions)
Non-vested units as of December 31, 20207,080 $11.35   
Granted2,790 $17.77   
Vested(1,555)$16.67   
Forfeited(775)$13.45   
Non-vested units as of September 30, 20217,540 $13.81 2.4$72.0 
Schedule of Equity Compensation Expenses
The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:
 Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)2021202020212020
Equity compensation expense recognized in:
Research and development expense$3,775 $8,626 $13,232 $17,241 
Selling, general, and administrative expense8,066 7,282 30,699 19,671 
Total equity compensation expense$11,841 $15,908 $43,931 $36,912